Cancer Clinical Research Trials

The Thomas Johns Cancer Hospital is committed to offering our patients opportunities to participate in new clinical research trials.  This is part of our mission in offering the most advanced services available.  These trials are open to those who qualify.  Our research nurse coordinators will work with your physicians to discuss trials with you and your family. To learn if you qualify for these or other clinical research trials, please speak with your physician.  Studies opened and managed by the Virginia Cancer Institute (VCI) are noted as well as any study pending Institutional Review Board (IRB) approval.   

Protocols Open at TJCH:

Breast Cancer

BRE 163 - SCRI
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node Positive or High Risk Node Negative, HE2 Negative Breast Cancer. VCI Study

BRE 154 - SCRI
A Randomized, Double-Blind, Placebo-controlled Phase II Trail of Weekly Taxol /Bevacizamab+/- Everolimus as First-Line Chemotherapy for Patients with HER-2 Negative Metastatic Breast Cancer. VCI Study

BRE 133 - SCRI
Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer. VCI Study

BRE 128 - GSK EGF106708 ALTTO
A Randomized, Multi-Center, Open-
Label, Phase III Study of Adjuvant
Lapatinib, Trastuzumab, Their Sequence
and Their Combination in Patients with
HER2/ErbB2 Positive Breast Cancer.
VCI Study

BRE 139 – SCRI
Phase II Study of Neoadjuvant
Ixabepilone/Carboplatin/Trastuzumab in
HER2-Positive Locally Advanced Breast
Cancer.  VCI Study

BRE 145 – SCRI
Phase III Study of Doxorubicin /
Cyclophosphamide (AC) Followed by
Ixabepilone vs. AC Followed by
Paclitaxel in Patients with Triple-
Negative Early-Stage Breast Cancer. 
VCI Study

SCRI BRE 156
A Phase II Study of NK012 in Locally
Advanced Non-Resectable and
Metastatic Breast Cancer Patients with
Triple Negative Phenotype.  VCI Study

BRE 160 – Novartis Bolero 1
CRAD001J2301
A Randomized, Phase III, Double-Blind, Placebo Controlled, Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer

BRE 167 /Novartis/ BOLERO
CRAD001W2301
A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing locally advanced or metastatic breast cancer

SCRI BRE 174 / BiPar 2010EAP
An Open -Label, Expanded Access Protocol of BSI- 201 in Combination with Gemcitabine/ Carboplatin in Patients with ER-, PR -, and Her2 -Negative Metastatic Breast Cancer

VCU-Bradley
Breast Cancer, Health Insurance and Work study. VCI Study

GASTROINTESTINAL

GI 142 / Perifosine 34
A Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer

LUNG

SCRI LUN 186
Phase II Trial of Preoperative
Pemetrexed and Carboplatin in
Patients with Select Stage IB, II
and III Non-Squamous NSCLC. VCI study

SCRI LUN 196
Randomized Phase II Trial of
Pemetrexed vs. Pemetrexed /
Bevacizumab vs. Pemetrexed /
Carboplatin / Bevacizumab in
Patients with Stage IIIB / IV Non-
Small-Cell Lung Cancer and
ECOG Performance Status. VCI study

LUN 192 – Lilly H3E-MCJMHD
Randomized, Open-Label, Phase
3 Study of Pemetrexed plus
Carboplatin and Bevacizumab
Followed by Maintenance
Pemetrexed and Bevacizumab
versus Paclitaxel plus Carboplatin
and Bevacizumab Followed by
Maintenance Bevacizumab in
Patients with Stage IIIb or IV
Nonsquamous Non-Small Cell
Lung Cancer. VCI Study 
 

LUN 200
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib or Erlotinib and Placebo in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

LUN 201 / BiPar 20090321
Randomized Phase 3 Trial of Gemcitabine / Carboplatin with or without BSI-201 in Patients with Previously Untreated Advanced Squamous Cell Lung Cancer

SCRI LUN 199
A Phase II Trial of Amrubicin and Carboplatin with Pegfilgrastim in Patients with Extensive Stage Small Call Lung Cancer

LYMPHOMA

LYM 67 / Millennium C05013
An Open Label, Randomized, Phase 2 Study t0 Assess the Effectiveness of RCHOP with or without Velcade in Previously Untreated Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

*** Paraffin block must be available

LYM 68 / GSK OMB110918
An Open Label, Randomized, Phase 2 Study of OfatuMumab and Bendimustine Combination Therapy Compared with Bedimustine Monotherapy in Indolent B –Cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab- Containing Regimen During or Within 6 Months of Treatment

LYM 64 - Cephalon C18083
An Open Label, Randomized, Study of Bendamustine and Rituxan (BR) versus Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma  or Mantle Cell Lymphoma. VCI Study

MELANOMA

MEL 20 / Lilly H8K-MC-JZAO
A Randomized Phase III Study of Tasisulam Administered IV on day 1 of a 28 Day Cycle vs. Taxol as 2nd Line Treatment in Patients with Unresectable or Metastatic Melanoma

PROSTATE

SCRI GU 63 /Medivation/ AFFIRM CRPC2 
Phase III, Randomized, Double-Blind, Placebo Controlled Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

GU 64 Celgene CC-5013-PC-002 
A phase III Study to Evaluate the Efficacy and Safety of Doxetaxol and Prednisonewith or without Lenolidomide in Subjects with Castrate-Resistant Prostate Cancer.

***Note 6 week washout for Casodex***

RTOG 0534 
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy; CJW2009-012

RENAL CELL

GU 56 – SCRI
A Phase II Trial of Pazopanib in
Patients with Metastatic Renal
Cell Carcinoma Previously
Treated with Sunitinib or
Bevacizumab.  VCI Study

UNKNOWN PRIMARY

UNK PRI 21/TopoTarget A/S
PXD101-CLN-17
An open-label randomized phase
II trial of belinostat (PXD101) in
combination with carboplatin and
paclitaxel (BelCaP) compared to
carboplatin and paclitaxel in
patients with previously untreated
carcinoma of unknown primary. VCI Study

OTHER

Partial Breast Irradiation
A prospective evaluation of catheter failure rates and skin reactions in patients receiving accelerated partial breast irradiation; CJW2007-008

National Oncology PET Registry (NOPR)
This study is a registry with the aim of determining clinical benefit in designing individual care plans based on information obtained from additional tests; CJW2009-004.

Cancer Survivorship 
A trial for cancer survivors to determine education and supportive service needs; CJW2007-017